• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

粪便血红蛋白免疫化学检测联合粪便转铁蛋白用于结直肠癌筛查

Fecal immunochemical test for hemoglobin in combination with fecal transferrin in colorectal cancer screening.

作者信息

Gies Anton, Cuk Katarina, Schrotz-King Petra, Brenner Hermann

机构信息

Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.

出版信息

United European Gastroenterol J. 2018 Oct;6(8):1223-1231. doi: 10.1177/2050640618784053. Epub 2018 Jun 12.

DOI:10.1177/2050640618784053
PMID:30288285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6169043/
Abstract

OBJECTIVE

Fecal transferrin has been suggested as a complementary or even superior marker for early detection of colorectal cancer (CRC) besides fecal hemoglobin. We aimed to evaluate both markers individually and in combination in a large cohort of participants of screening colonoscopy.

METHODS

Precolonoscopy stool samples were obtained from participants of screening colonoscopy and frozen at -80℃ until blinded analysis, using a dual-quantitative fecal immunochemical test (FIT) for hemoglobin and transferrin. Sensitivity, specificity and area under the curve (AUC) were calculated for CRC and advanced adenoma (AA).

RESULTS

A total of 1667 participants fulfilled our inclusion criteria. All individuals with advanced neoplasm (AN) (16 CRC, 200 AA) and 300 randomly selected participants without AN were included. Mean age was 63 years and 56% were male. The AUC for CRC and AA was 92% and 68%, respectively, for hemoglobin vs. 79% and 58%, respectively for transferrin. Combination of both markers yielded an AUC for CRC and AA of 92% and 68%, respectively.

CONCLUSION

FIT for hemoglobin shows better diagnostic performance than FIT for transferrin for the detection of ANs (both proximal and distal neoplasms), and a combination of both markers does not improve the diagnostic performance.

摘要

目的

除粪便血红蛋白外,粪便转铁蛋白已被认为是早期检测结直肠癌(CRC)的一种补充性甚至更优的标志物。我们旨在对大量结肠镜筛查参与者队列中的这两种标志物进行单独及联合评估。

方法

从结肠镜筛查参与者中获取结肠镜检查前的粪便样本,并在-80℃下冷冻,直至采用针对血红蛋白和转铁蛋白的双定量粪便免疫化学检测(FIT)进行盲法分析。计算CRC和高级别腺瘤(AA)的敏感性、特异性和曲线下面积(AUC)。

结果

共有1667名参与者符合我们的纳入标准。纳入了所有患有高级别肿瘤(AN)的个体(16例CRC,200例AA)以及300名随机选择的无AN的参与者。平均年龄为63岁,56%为男性。对于CRC和AA,血红蛋白的AUC分别为92%和68%,而转铁蛋白的AUC分别为79%和58%。两种标志物联合使用时,CRC和AA的AUC分别为92%和68%。

结论

用于检测血红蛋白的FIT在检测AN(近端和远端肿瘤)方面比用于检测转铁蛋白的FIT具有更好的诊断性能,且两种标志物联合使用并不能提高诊断性能。

相似文献

1
Fecal immunochemical test for hemoglobin in combination with fecal transferrin in colorectal cancer screening.粪便血红蛋白免疫化学检测联合粪便转铁蛋白用于结直肠癌筛查
United European Gastroenterol J. 2018 Oct;6(8):1223-1231. doi: 10.1177/2050640618784053. Epub 2018 Jun 12.
2
The Addition of Other Fecal Biomarkers Does Not Improve the Diagnostic Accuracy of Immunochemical Fecal Occult Blood Test Alone in a Colorrectal Cancer Screening Cohort.在结直肠癌筛查队列中,添加其他粪便生物标志物并不能提高单独免疫化学粪便潜血试验的诊断准确性。
Front Med (Lausanne). 2021 Jun 4;8:665786. doi: 10.3389/fmed.2021.665786. eCollection 2021.
3
Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.用于结直肠癌筛查的粪便潜血试验:一项基于证据的分析。
Ont Health Technol Assess Ser. 2009;9(10):1-40. Epub 2009 Sep 1.
4
[Diagnostic performance of quantitative fecal immunochemical test in detection of advanced colorectal neoplasia].[定量粪便免疫化学检测在晚期结直肠肿瘤检测中的诊断性能]
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Dec 10;41(12):2104-2111. doi: 10.3760/cma.j.cn112338-20191216-00888.
5
Screening for colon cancer: A test for occult blood.结肠癌筛查:一项潜血检测。
Int J Risk Saf Med. 2015;27 Suppl 1:S110-1. doi: 10.3233/JRS-150712.
6
Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.新一代粪便免疫化学检测(FIT)与愈创木脂粪便潜血试验(gFOBT)在结肠镜转诊患者中检测结直肠肿瘤的比较。
Anticancer Res. 2019 Jan;39(1):261-269. doi: 10.21873/anticanres.13106.
7
[The clinical value of multi-target stool fecal immunochemical test-DNA in early screening and diagnosis for colorectal cancer].多靶点粪便免疫化学检测-DNA在结直肠癌早期筛查与诊断中的临床价值
Zhonghua Yi Xue Za Zhi. 2022 Sep 6;102(33):2607-2613. doi: 10.3760/cma.j.cn112137-20220430-00974.
8
A fecal-based test for the detection of advanced adenoma and colorectal cancer: a case-control and screening cohort study.基于粪便的检测用于高级腺瘤和结直肠癌的检测:病例对照和筛查队列研究。
BMC Med. 2021 Oct 25;19(1):250. doi: 10.1186/s12916-021-02123-0.
9
A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.新一代粪便免疫化学检测(FIT)在结肠镜检查转诊患者中检测结直肠肿瘤方面优于基于愈创木脂的检测。
Anticancer Res. 2015 May;35(5):2873-80.
10
Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.癌症筛查中的粪便免疫化学检测——粪便免疫化学检测阳性和阴性者的结肠镜检查结果
Scand J Gastroenterol. 2019 Mar;54(3):303-310. doi: 10.1080/00365521.2019.1585569. Epub 2019 Mar 23.

引用本文的文献

1
A Point-of-Care Faecal Test Combining Four Biomarkers Allows Avoidance of Normal Colonoscopies and Prioritizes Symptomatic Patients with a High Risk of Colorectal Cancer.一种结合四种生物标志物的即时粪便检测可避免正常结肠镜检查,并优先处理有高风险的有症状结直肠癌患者。
Cancers (Basel). 2023 Jan 24;15(3):721. doi: 10.3390/cancers15030721.
2
A fluorescent microsphere-based immunochromatographic strip is effective for quantitative fecal blood testing in colorectal cancer screening.基于荧光微球的免疫层析试纸条在结直肠癌筛查中用于粪便潜血定量检测效果良好。
Am J Transl Res. 2022 Mar 15;14(3):2123-2132. eCollection 2022.
3
A Patient Self-Made Point-of-Care Fecal Test Improves Diagnostic Accuracy Compared with Fecal Calprotectin Alone in Inflammatory Bowel Disease Patients.与单独使用粪便钙卫蛋白相比,一种患者自制的即时粪便检测提高了炎症性肠病患者的诊断准确性。
Diagnostics (Basel). 2021 Dec 10;11(12):2323. doi: 10.3390/diagnostics11122323.
4
The Addition of Other Fecal Biomarkers Does Not Improve the Diagnostic Accuracy of Immunochemical Fecal Occult Blood Test Alone in a Colorrectal Cancer Screening Cohort.在结直肠癌筛查队列中,添加其他粪便生物标志物并不能提高单独免疫化学粪便潜血试验的诊断准确性。
Front Med (Lausanne). 2021 Jun 4;8:665786. doi: 10.3389/fmed.2021.665786. eCollection 2021.
5
The Roadmap of Colorectal Cancer Screening.结直肠癌筛查路线图
Cancers (Basel). 2021 Mar 4;13(5):1101. doi: 10.3390/cancers13051101.
6
Fecal DNA Testing of TWIST1 Methylation Identifies Patients With Advanced Colorectal Adenoma Missed by Fecal Immunochemical Test for Hemoglobin.粪便 TWIST1 甲基化 DNA 检测可识别粪便血红蛋白免疫化学检测漏检的进展期结直肠腺瘤患者。
Clin Transl Gastroenterol. 2020 Jun;11(6):e00176. doi: 10.14309/ctg.0000000000000176.

本文引用的文献

1
Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening.9 种用于结直肠癌筛查的定量粪便免疫化学检测方法的诊断性能直接比较。
Gastroenterology. 2018 Jan;154(1):93-104. doi: 10.1053/j.gastro.2017.09.018. Epub 2017 Sep 25.
2
Strong subsite-specific variation in detecting advanced adenomas by fecal immunochemical testing for hemoglobin.粪便血红蛋白免疫化学检测检测进展性腺瘤的亚部位特异性变化很大。
Int J Cancer. 2017 May 1;140(9):2015-2022. doi: 10.1002/ijc.30629. Epub 2017 Feb 14.
3
Fresh vs Frozen Samples and Ambient Temperature Have Little Effect on Detection of Colorectal Cancer or Adenomas by a Fecal Immunochemical Test in a Colorectal Cancer Screening Cohort in Germany.新鲜样本与冷冻样本及室温对粪便免疫化学试验检测德国结直肠癌筛查队列中结直肠癌或腺瘤的影响较小。
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1547-1556.e5. doi: 10.1016/j.cgh.2016.10.018. Epub 2016 Oct 26.
4
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.结直肠癌筛查:美国预防服务工作组推荐声明。
JAMA. 2016 Jun 21;315(23):2564-2575. doi: 10.1001/jama.2016.5989.
5
Fecal Immunochemical Tests Combined With Other Stool Tests for Colorectal Cancer and Advanced Adenoma Detection: A Systematic Review.粪便免疫化学检测联合其他粪便检测用于结直肠癌和晚期腺瘤检测:一项系统评价
Clin Transl Gastroenterol. 2016 Jun 2;7(6):e175. doi: 10.1038/ctg.2016.29.
6
STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies.STARD 2015:报告诊断准确性研究的必备项目更新清单。
BMJ. 2015 Oct 28;351:h5527. doi: 10.1136/bmj.h5527.
7
Colorectal cancer screening: a global overview of existing programmes.结直肠癌筛查:现有项目的全球概览。
Gut. 2015 Oct;64(10):1637-49. doi: 10.1136/gutjnl-2014-309086. Epub 2015 Jun 3.
8
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡:GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
9
Multitarget stool DNA testing for colorectal-cancer screening.多靶点粪便 DNA 检测用于结直肠癌筛查。
N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.
10
Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist.改进粪便血红蛋白免疫化学检测评估报告:FITTER标准与清单
Eur J Cancer Prev. 2015 Jan;24(1):24-6. doi: 10.1097/CEJ.0000000000000016.